Celentyx's, which applies the powerful to the development of reprofiled drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug targets Celentyx's enable partners to elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man